Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Celregen Raises Funds for Cell Therapies in Angel Round

publication date: Sep 20, 2024

Hangzhou Celregen Therapeutics raised “tens of millions RMB” to advance its regenerative medicine and cell therapy products. The company is a subsidiary of Fosun Pharma that was incubated by the New Drug Fund of Fosun Health Capital. Fosun’s New Drug Fund also led the latest angel round together with the Jiaxing Chuangyan Fund of Shanghai Creation Investment. During its corporate life, Celregen has been operating mostly in stealth mode, though two years ago, it briefly surfaced to announce it had in-licensed Greater China rights for a corneal endothelial cell regenerative therapy from Cellusion in a $100 million deal. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here